Preparing your experience...
Preparing your experience...
Pharma Transparency Report
Every number on this page comes from the FDA's own Adverse Event Reporting System (FAERS) and the European Medicines Agency. Pharma companies are legally required to report this data. The problem is nobody makes it easy to find. Until now.
Data queried live from FDA FAERS and EMA via AlgoVigilance Station MCP tools. Last updated March 2026.
Source: openFDA FAERS. Reports ≠ proven causation, but every one was filed with the FDA.
| Company | Total Reports | Serious | Deaths | Seriousness | Top Problem Drug |
|---|---|---|---|---|---|
| Pfizer | 2,365,741 | 1,496,929 | 79,684 | 63.3% serious | Gabapentin (348,412) |
| AbbVie | 1,443,745 | 864,600 | 44,284 | 59.9% serious | Adalimumab (Humira) (695,824) |
| Novartis | 1,160,661 | 753,018 | 67,394 | 64.9% serious | Secukinumab (157,236) |
| Johnson & Johnson | 1,069,207 | 778,190 | 26,993 | 72.8% serious | Infliximab (Remicade) (209,293) |
| Eli Lilly | 960,350 | 441,575 | — | 46% serious | Duloxetine (Cymbalta) (139,162) |
| Bristol-Myers Squibb | 333,253 | 235,699 | 19,470 | 70.7% serious | Abatacept (Orencia) (133,225) |
Company Deep Dive
460,922 total adverse event reports across 6 key drugs. Source: FDA FAERS.
Lansoprazole · Heartburn / GERD
173,092
Reports
19,350
Deaths
62,821
Hospital
OTC heartburn pill with 19,350 death reports
Bortezomib · Multiple myeloma
86,297
Reports
13,727
Deaths
27,730
Hospital
Vedolizumab · Ulcerative colitis / Crohn's
80,189
Reports
3,916
Deaths
23,794
Hospital
#1 adverse event: OFF LABEL USE (21,828 reports)
Leuprolide · Prostate cancer / endometriosis
76,674
Reports
11,688
Deaths
11,854
Hospital
Ixazomib · Multiple myeloma
28,427
Reports
5,259
Deaths
8,703
Hospital
#2 most reported adverse event: DEATH (3,297)
Vortioxetine · Major depressive disorder
16,243
Reports
958
Deaths
2,691
Hospital
898 suicidal ideation + 283 suicide attempts + 275 completed suicides
An antidepressant with 898 reports of suicidal ideation, 283 suicide attempts, and 275 completed suicides in the FDA database. The drug prescribed to prevent these exact outcomes.
898
Suicidal Ideation
283
Suicide Attempts
275
Completed Suicides
Correlation does not prove causation. But transparency is your right. All antidepressants carry an FDA black box warning for suicidality in patients under 25.
Signal Investigation
Disproportionality analysis (PRR/ROR) computed via OpenVigil against the full FAERS database of 20M+ reports. All five antidepressants show strong signals.
| Drug | Cases | PRR | ROR | IC | Chi-squared | Signal |
|---|---|---|---|---|---|---|
| Fluoxetine (Prozac) | 3,678 | 7.44 | 7.63 | 2.84 | 19,625 | STRONG |
| Escitalopram (Lexapro) | 2,485 | 4.71 | 4.78 | 2.20 | 7,054 | STRONG |
| Vortioxetine (Trintellix) | 275 | 4.22 | 4.28 | 2.07 | 673 | STRONG |
| Sertraline (Zoloft) | 3,246 | 3.94 | 3.99 | 1.94 | 6,865 | STRONG |
| Duloxetine (Cymbalta) | 2,599 | 3.64 | 3.68 | 1.83 | 4,840 | STRONG |
Key finding: Fluoxetine (Prozac) has the highest PRR at 7.44x— meaning completed suicide is reported 7.4 times more often than expected. Vortioxetine (Trintellix) ranks 3rd by PRR (4.22x) but has the fewest absolute cases (275), likely due to smaller market share rather than superior safety. All five drugs exceed the signal detection threshold (PRR ≥ 2.0, chi-squared ≥ 4.0).
Lansoprazole (Prevacid) — No signal for death: Despite 19,350 death reports, the disproportionality analysis shows PRR = 0.64 (below 1.0). This means lansoprazole is reported with death less often than the average drug in FAERS. The high absolute count reflects massive prescribing volume (millions of daily users), not a safety signal. This is why raw numbers without statistical context can be misleading — and why tools like disproportionality analysis exist.
Signal Investigation #2
Semaglutide (Ozempic/Wegovy), tirzepatide (Mounjaro), and liraglutide (Victoza) — do they cause sarcopenia? Does tirzepatide's GIP receptor protect muscle?
| MSK Event | Semaglutide | Tirzepatide | Liraglutide | Cascade |
|---|---|---|---|---|
| Sarcopenia | 9.98 | 3.62 | 3.30 | SIGNAL |
| Muscle Atrophy | 3.95 | 2.28 | 1.05 | SIGNAL |
| Muscular Weakness | 0.93 | 0.28 | 0.74 | No signal |
| Myalgia | 0.98 | 0.60 | 0.73 | No signal |
| Rhabdomyolysis | 0.66 | 0.17 | 0.65 | No signal |
| Osteopenia | 0.47 | 0.14 | 0.58 | No signal |
| Fall | 1.05 | 0.23 | 0.81 | No signal |
| Hip Fracture | 0.51 | 0.10 | 0.45 | No signal |
Semaglutide (Ozempic)
PRR 9.98
14 sarcopenia cases. 10x the expected rate. Worst of the three GLP-1 drugs.
Tirzepatide (Mounjaro)
PRR 3.62
8 cases. GIP receptor co-activation provides 2.8x protection vs semaglutide.
Time-to-Onset
6 months
Median onset 180 days (IQR 5-8.5 months). Weibull k=2.75 = late accumulation hazard.
Key finding: The cascade breaks at the muscle-bone boundary. All three GLP-1 drugs show strong signals for muscle-level events (sarcopenia, atrophy) but noneshow disproportionate reporting for downstream consequences (weakness, osteopenia, falls, hip fracture). This could mean the cascade hasn't had time to develop at population scale, or that confounders (obesity's protective effect on bone density) mask downstream signals.
Neither drug's label mentions sarcopenia. The FDA has not required a boxed warning or labeling change for muscle wasting despite a PRR of 9.98 for semaglutide.
How bad does it get? Death, hospitalization, and life-threatening events for high-profile drugs.
| Drug | Deaths | Hospitalizations | Life-Threatening | Seriousness |
|---|---|---|---|---|
| Rivaroxaban (Xarelto) | 26,830 | 102,060 | 9,191 | 84% serious |
| Adalimumab (Humira) | 30,115 | 150,426 | 12,002 | 51.3% serious |
| Nivolumab (Opdivo) | 24,022 | 37,923 | 6,424 | 89.5% serious |
| Gabapentin (Neurontin) | 33,678 | 103,607 | 10,328 | 63.2% serious |
| Tirzepatide (Mounjaro) | 652 | 7,276 | 934 | 16.7% serious |
162 active drug safety communications from the European Medicines Agency (EMA). Drugs suspended, withdrawn, or under new restrictions.
Class I = most dangerous classification. Reasonable probability of serious adverse health consequences or death.
Pfizer subsidiary Hospira recalled multiple injectable drug syringes contaminated with glass particles — including chemotherapy drugs, cardiac emergency medications, and anesthetics. 4 recalls still ongoing as of 2024.
One batch of Propofol (the anesthetic Michael Jackson died from) was recalled because a vial contained a beetle.
Glass Found
Bleomycin (chemo)
Glass Found
Sodium Bicarbonate (emergency)
Glass Found
Atropine (cardiac)
Glass Found
Lidocaine (anesthetic)
None of this is conspiracy. It is publicly mandated reporting data sitting in government databases almost nobody knows how to query. The companies report it because they are legally required to. The “hiding” is that the data is buried in systems designed by bureaucrats, not for patients.
Every query on this page was executed in under 3 seconds using AlgoVigilance Station — an open pharmacovigilance intelligence layer that any AI agent can connect to.
The data was always yours. Now you can actually read it.